Last updated on April 2018

A Bronchoprovocation Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma


Brief description of study

This is a non-confirmatory, randomized, subject and investigator blinded, placebo-controlled, parallel-design, multi-center bronchoprovocation study. Approximately 55 subjects with mild stable atopic asthma who exhibit an EAR and LAR to a common inhaled allergen will receive multiple once daily doses of inhaled CSJ117 or placebo over 12 weeks. Two sequential dose cohorts are planned for this study, Cohort 1 and Cohort 2. Cohort 2 will be split into two parts, Cohort 2a and 2b

Clinical Study Identifier: NCT03138811

Find a site near you

Start Over

Novartis Investigative Site

Quebec, QC Canada
4.9miles
  Connect »